ECKERT & ZIEGLER

DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application

Retrieved on: 
Tuesday, November 30, 2021
Patient, CEO, Toronto Rehabilitation Institute, UHN, University, European Medicines Agency, Radiopharmaceutical, Lymphoma, Lung cancer, The Michener Institute, Toronto Western Hospital, Diagnosis, News, Center, Partnership, Cancer, CXCR4, DGAP, Cardiology, Education, TecDAX, Deutsch, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Physician, University Health Network, Commercialization, Research, Health, EMA, Arthritis, ISIN, PET, Neuroscience, Transplant, Reinvigorating Antibiotics and Diagnostic Innovation (READI) Act, Infection, Oncology, Nuclear medicine, Security (finance), Pharmaceutical industry, Medical imaging, Eckert & Ziegler, CanProbe, ECKERT & ZIEGLER, CANPROBE

The partnership involves clinical research to further advance PentixaPharm's Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.

Key Points: 
  • The partnership involves clinical research to further advance PentixaPharm's Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX) and its subsidiary, PentixaPharm GmbH, are working with CanProbe and UHN to provide PENTIXAFOR to patients in Toronto.
  • The intent is to provide further support toward the approval of PENTIXAFOR as a diagnostic agent for a portfolio of different indications.
  • "We are delighted to see this partnership emerging between PentixaPharm, CanProbe, and UHN", adds Luke Brzozowski, Senior Director, Techna and Diagnostics Innovation, University Health Network.

DGAP-News: Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States

Retrieved on: 
Thursday, June 3, 2021
Branches of biology, Nuclear medicine, Medicine, Radiation therapy, Medicinal radiochemistry, Medical imaging, Medical physics, Glutamate carboxypeptidase II, Peptidase, Prostate cancer, Eckert, Positron emission tomography, Eckert & Ziegler, Telix Pharmaceuticals, Illuccix(R), ECKERT & ZIEGLER, TELIX PHARMACEUTICALS, ILLUCCIX(R)

Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm(R) (68Ge/68Ga Generator) and investigational product Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in the United States.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm(R) (68Ge/68Ga Generator) and investigational product Illuccix(R) (Kit for the preparation of Ga-68 PSMA-11 injection) in the United States.
  • Illuccix(R) is a preparation for imaging prostate cancer by positron emission tomography (PET) and is currently under review for regulatory approval in the United States and multiple markets worldwide.
  • Eckert & Ziegler and Telix will expand their existing collaboration to further develop access to Ga-68 supply in the United States.
  • "We are pleased to have Telix as a partner and to be able to jointly provide leading edge diagnostic products to prostate cancer patients in the USA."